Fischer Medical Ventures launches Chennai's first high-resolution open MRI at Sunray Scans
The launch event, held on July 21, 2025, was graced by Thiru Udhayanidhi Stalin, Honourable Deputy Chief Minister of Tamil Nadu. This state-of-the-art MRI system is engineered to deliver superior diagnostic clarity while addressing common challenges like claustrophobia and noise-induced anxiety. A breakthrough in patient-friendly imaging
The newly installed PICA Open MRI combines cutting-edge imaging technology with an open architecture design that eliminates the traditional tunnel structure. This innovation significantly reduces anxiety and discomfort for children, elderly patients, obese individuals, and those with claustrophobia.
Backed by AI-assisted algorithms and optimized RF technology, the system delivers high-resolution images for neurological and musculoskeletal applications without compromising quality. The MRI is also eco-friendly, with up to 40% lower energy consumption compared to traditional systems, no cryogen handling, and minimal infrastructure needs. Key features of the PICA Open MRI: Open design, eliminating the enclosed tunnel
Low-noise, comfortable scanning experience
High-resolution imaging with HTS (High Temperature Superconductor) coil technology
Supports patients up to 250 kg
Helium-free and radiation-free, making it environmentally safe
Dr. A. Subair Khan, Founder and Managing Director of Orthomed Hospital, highlighted that this system provides exceptional comfort for infants, elderly, and claustrophobic patients, while also offering crystal-clear diagnostic images and quiet operation.
Sunray Scans, a unit of Orthomed, in association with Time Medical International Ventures (India) Pvt. Ltd., a wholly-owned subsidiary of Fischer Medical Ventures and a global innovator in diagnostic imaging, installed the MRI system.
The company reiterated its commitment to making advanced, accessible, and affordable healthcare a reality by integrating cutting-edge technology with patient-centric care. About the company
Fischer Medical Ventures Limited is a healthcare technology company engaged in bringing innovative medical imaging solutions to the Indian market. Its subsidiary, Time Medical International Ventures, spearheaded the installation of the PICA Open MRI in Chennai.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
Imaging Boom Drives Cancer Detection and Healthcare Growth
Cancer is a condition where cells in a specific part of the body start multiplying out of control, often clumping together to form tumors. Doctors can identify cancer using different kinds of tests, including imaging scans, endoscopy, tumor marker tests, biopsies, complete blood counts, and MRI scans. Major growth factor consist of large number of clinics have adopted tools for cancer detection like MRI, CT-scans and other. This has led to growth in healthcare sector and global economy. It is also a milestone for healthcare services. Key Growth Drivers and Opportunities Growing Incidence of Cancer: The increasing prevalence and incidences of various types of cancer like lung cancer and breast cancer, help the cancer diagnostics market to grow significantly during the forecast period. According to estimates, 1 in 100 (or 1% yearly) of those 70 years of age or over lost their lives to cancer in 2019. Overall death toll is rising in tandem with the world's population growth. From roughly 46 million in 1990 to 56 million in 2019, there have been more fatalities. Most cancer deaths occur in elderly adults. Rising Expenditure of Healthcare: The cost estimates cover both prescription medications taken by mouth and medical treatments for cancer. The most expensive medical services nationally were linked to non-Hodgkin lymphomas, as well as cancers of the prostate, lung, colon, and female breast. Medical services care costs, which comprise Medicare payments as well as patient obligations for all billed medical services, such as hospitalizations, outpatient hospital services, physician/supplier services, infusion or injectable drug, durable medical equipment, and hospice care, were estimated from Medicare Parts A and B claims. Challenges The implementing cancer diagnostics can require significant upfront investment, including the cost of the software itself, customization, and integration with existing systems. This can be a barrier for smaller hospitals with limited budgets. The regulatory landscape for cancer diagnostics is constantly evolving, with new guidelines and requirements emerging regularly. Keeping up with these changes and adjusting reporting practices accordingly can be a daunting task for companies Innovation and Expansion Guardant, Boehringer Team Up on HER2 NSCLC Liquid Biopsy In December 2024, the Guardant Health, Inc. announced a partnership with Boehringer Ingelheim aimed at obtaining regulatory approval and advancing the commercialization of the Guardant360 CDx liquid biopsy. This partnership is all about using liquid biopsy as a companion diagnostic (CDx) for zongertinib. Zongertinib is a new type of drug called a covalent tyrosine kinase inhibitor (TKI) designed to specifically target HER2 in non-small cell lung cancer (NSCLC), while minimizing the impct on the epidermal growth factor receptor (EGFR). GE, GenesisCare Partner to Tackle Cancer and Heart Disease In November 2020, GE Healthcare entered into partnership with GenesisCare to improve patient outcomes for the two biggest health burdens globally, cancer and heart disease. GE Healthcare will provide CT, MRI, PET/CT, SPECT, digital mammography, and ultrasound equipment to GenesisCare's 440+ cancer and cardiovascular disease treatment centers across Australia, the US, the UK, and Spain This partnership is all about boosting how accurately we can diagnose conditions and making treatment plans smoother, all thanks to state-of-the-art imaging tech. With GE Healthcare's innovative tools, GenesisCare can really speed up spotting issues early on and providing tailored care for folks dealing with cancer or heart-related conditions. Inventive Sparks, Expanding Markets The Key players in the global cancer diagnostics market includes, Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company among others. As major key players, they're effectively striving in innovation to make sure consumers globally can benefit from modern healthcare tech and to really elevate the overall experience for patients everywhere. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Time Business News
an hour ago
- Time Business News
The Future of Regenerative Medicine Unfolds
Synthetic stem cell lab-engineers are cell mimic designed to repeat the therapeutic effects of natural stem cells without living cell therapy, such as immune rejection or risks associated with tumor formation. These synthetic options often use biometrics or nanoparticles to distribute regenerative signals and therapeutic molecules. Market safe for synthetic stem cells, more scalable regenerative medical solutions, progression in biometric and nanotechnology and increasing demand due to increasing demand due to increased prevalence of chronic diseases and tissue injuries, requiring innovative, low -risk treatment options. Key Growth Drivers and Opportunities Progression in Biometric and Nanotechnology: Progress in biometrics and nanotechnology is significantly running the development of the synthetic stem cell market by enabling the accurate design and construction of the cell-mimicking system repeating natural stem cells. Nanotechnology enhances targeted distribution, bio -purpose and controlled release of therapeutic agents, while biometric advanced cell surface helps to mimic the surface markers and signaling the necessary routes for tissue regeneration. These innovations not only improve the safety and efficacy of synthetic stem cell therapy, but also make them more scalable and adaptable for various clinical applications, which accelerate their adoption in regenerative therapy. Challenges The synthetic stem cell market faces several borders, including challenges in completely imitating complex biological functions and adaptability of natural stem cells. Issues such as limited long-term efficacy, potential immune reactions and scalability of high-loyal synthetic cells can obstruct widely adopting. Additionally, the requirement of regulator uncertainty and extensive clinical verification slows down commercialization and integration in mainstream treatments. These obstacles must be addressed to feel the full potential of synthetic stem cell technologies in regenerative medicine. Innovation and Expansion Next-Gen Stem Cell Products for Regenerative Medicine Revealed by Bioserve India In July 2024, with great pleasure, Bioserve India announced the arrival of its cutting-edge stem cell products in India. With the help of these new REPROCELL solutions, the Indian market will see advances in regenerative medicine and therapeutic discoveries as well as innovation in scientific research and medication development. The market for stem cells is a quickly expanding sector that includes a variety of goods and services. Many sectors of the stem cell market are involved in vital tasks such product development, production, and distribution of stem cell treatment. New medicines and improvements in healthcare are anticipated as a result of this launch, which is anticipated to stimulate stem cell research and therapeutic development in India. The First Scientific Development of Synthetic Human Embryos without Sperm or Egg In June 2023, in an innovative development that avoids the need for eggs or sperm, scientists have used stem cells to produce synthetic human embryos. These model embryos, which are similar to those in the early phases of human development, may offer a vital insight into the effects of genetic diseases and the biochemical reasons for repeated miscarriages, according to scientists. As scientists are only legally permitted to nurture embryos in the lab for a maximum of 14 days, the effort is motivated by the desire to help scientists grasp the so-called 'black box' stage of development. Pregnancy scans and research-donated embryos are then used to pick up the development considerably farther along. Inventive Sparks, Expanding Markets The key players operating the synthetic stem cells market involves Sangamo Therapeutics, Athersys, Pluristem Therapeutics, Cellular Biomedicine Group, Vericel, BrainstormCell Therapeutics, Caladrius Biosciences, Cytori Therapeutics, Cesca Therapeutics, VistaGen Therapeutics. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Miami Herald
5 hours ago
- Miami Herald
Trawlers snag ‘large'-eyed sea creature in a first-of-its-kind catch for India
Off the coast of southern India, trawlers hauled in their nets and started sifting through the catch. A pale brown sea creature with 'large' eyes caught their attention — and for good reason. It turned out to be a first-of-its-kind record. A team of scientists visited a fish landing center in Kollam, Kerala, in November 2023 to see what local trawlers were bringing in. Their focus wasn't the main hauls but rather the accidental catches, according to a study published July 18 in the peer-reviewed journal Acta Ichthyologica et Piscatoria. During the visit, researchers noticed four 'light brown' eels, the study said. Intrigued, they took a closer look at the fish and identified them as blackedge cusk eels, or Ophidion muraenolepis. Blackedge cusk eels are a poorly known fish species found throughout 'the eastern Indian Ocean and the western Pacific' from Indonesia to Hawaii, researchers said. The Kerala trawlers' catch is 'the first record of this species in Indian waters and the western Indian Ocean.' A photo shows one of the blackedge cusks caught off Kerala. The fish has 'large' 'pale greyish brown eyes,' a 'large' mouth and 'basket weave pattern scales,' the study said. As its name implies, its tail fin is edged with a 'black margin.' Information about blackedge cusk eels is 'scarce,' but the species's lifestyle is probably similar to that of other cusk eels, the study said. Generally, cusk eels are 'rare' and 'exhibit cryptic, burrowing behavior during (the) day making them more difficult to capture,' researchers said. Their eggs are 'encapsulated within a gelatinous mass,' and their diet 'primarily consists of small crustaceans,' such as shrimp. Researchers identified the blackedge cusk eels in Kerala by their coloring, fin shape and other subtle physical features. 'These findings underscore the importance of increased scientific investment towards comprehensive biodiversity assessments and taxonomic research focused on the ichthyofauna (fish) of the Indian Ocean,' the study said. The research team included Teena Jayakumar, Ronald Fricke, T. T. Ajith Kumar and Uttam Kumar Sarkar.
